Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in experimental animals and its relationship to corneal injury

Toxicology and Applied Pharmacology

Volumn 215, Issue 1, 2006, Pages 9-16

  Lock, Edward A ^a   Gaskin, Peter ^a   Ellis, Martin ^a   Provan, William M ^a   Smith, Lewis L ^a  

^a JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

Author keywords

2 (2 Nitro 4 trifluoromethylbenzoyl) cyclohexane 1,3 dione (NTBC); 4 Hydroxyphenylpyruvate dioxygenase (HPPD); Beagle dog; Corneal lesions; Rabbit; Rhesus monkey; Tyrosine aminotransferase (TAT); Tyrosinemia

Indexed keywords

HOMOGENTISATE 1,2 DIOXYGENASE; HOMOGENTISIC ACID; NITISINONE; OXIDOREDUCTASE; TYROSINE; TYROSINE AMINOTRANSFERASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; CHEMICAL MUTAGENESIS; CONTROLLED STUDY; CORNEA INJURY; CORNEA LESION; CORNEA OPACITY; DOG; DOSE TIME EFFECT RELATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RABBIT; RHESUS MONKEY; TISSUE INJURY; TYROSINEMIA;

ANIMALS; CORNEA; CYCLOHEXANONES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMOGENTISATE 1,2-DIOXYGENASE; MACACA MULATTA; MALE; NITROBENZOATES; RABBITS; TYROSINE TRANSAMINASE; TYROSINEMIAS;

ANIMALIA; CANIS FAMILIARIS; MACACA MULATTA; ORYCTOLAGUS CUNICULUS;

EID: 33746380246     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.01.015     Document Type: Article

References (33)

1. Ahmad S., Teckman J.H., and Leuder G.T. Corneal opacities associated with NTBC treatment. Am. J. Ophthalmol. 134 (2002) 266-268
2. Ambrose J.A. Fluorometric measurement of tyrosine in serum and plasma. Clin. Chem. 20 (1974) 505-510
3. Bito L.Z., Davson H., Levin E., Murray M., and Snider N. The relationship between concentrations of amino acids in the ocular fluids and blood plasma of dogs. Exp. Eye Res. 4 (1965) 374-380
4. Bohnert A., and Anton-Lamprecht I. Richner-Hanhart's syndrome: ultrastructural abnormalities of epidermal keratinisation indicating a causal relationship to high intracellular tyrosine levels. J. Invest. Dermatol. 79 (1982) 68-74
5. Brownlee J.M., Johnson-Winters K., Harrison D.H.T., and Moran G.R. Structure of the ferrous form of (4-hydroxyphenyl)pyruvate dioxygenase from Streptomyces avermitilis in complex with the therapeutic herbicide, NTBC. Biochemistry 43 (2004) 6370-6377
6. Coufalik A., and Monder C. Perinatal development of the tyrosine oxidising system. Biol. Neonate 34 (1978) 161-166
7. Dunn M.S., Ross F.J., and Read L.S. The solubility of the amino acids in water. J. Biol. Chem. 103 (1933) 579-595
8. Driscoll D.J., Jabs E.W., Alcorn D., Maumenee I.H., Brusilow S.W., and Valle D. Corneal tyrosine crystals in transient neonatal tyrosinemia. J. Pediatr. 113 (1988) 91-93
9. Edwards S.W., and Knox W.E. Homogentisate oxidase from rat liver. Methods Enzymol. 2 (1963) 292-295
10. Ellis M.K., Whitfield A.C., Gowan L.A., Auton T., Provan W.M., Lock E.A., and Smith L.L. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulphonylbenzoyl)-cyclohexane-1,3-dione. Toxicol. Appl. Pharmacol. 133 (1995) 12-19
11. Gipson I.K., Burns R.P., and Wolfe-Lande J.D. Crystals in corneal epithelial lesions of tyrosine-fed rats. Invest. Ophthalmol. 14 (1975) 937-941
12. Gissen P., Preece M.A., Willshaw H.A., and McKiernan P.J. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. J. Inherited Metab. Dis. 26 (2003) 13-16
13. Goldsmith L.A. Haemolysis induced by tyrosine crystals. Biochem. J. 158 (1976) 17-22
14. Goldsmith L.A. Molecular biology and molecular pathology of a newly described molecular disease-tyrosemia II (The Richner-hanhart Syndrome). Exp. Cell Biol. 46 (1978) 96-113
15. Goldsmith L., and Laberge A. Tyrosinaemia and related disorders. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic Basis of Inherited Disease (1989), McGraw-Hill, New York 547-562
16. Hall M.G., Wilks M.F., Provan W.M., Eksborg S., and Lumholtz B. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1,3-dione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br. J. Clin. Pharmacol. 52 (2001) 169-177
17. Holme E., and Lindstedt S. Nontransplant treatment of tyrosinemia. Clin. Liver Dis. 4 (2000) 805-814
18. Holme E., Lindstedt S., and Lock E.A. Treatment of tyrosinaemia type I with an enzyme inhibitor (NTBC). Int. Pediatr. 10 (1995) 41-43
19. Kavana M., and Moran G.R. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione. Biochemistry 42 (2003) 10238-10245
20. Lindstedt S., and Odelhog B. 4-Hydroxyphenylpyruvate dioxygenase from human liver. Methods Enzymol. 142 (1987) 139-142
21. Lindstedt S., Holme E., Lock E.A., Hjalmarson O., and Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340 (1992) 813-817
22. Lock E.A., Gaskin P., Ellis M.K., Provan W.M., Robinson M., Smith L.L., Prisbylla MP., and Mutter LC. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC): effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. Toxicol. Appl. Pharmacol. 141 (1996) 437-439
23. Lock E.A., Gaskin P., Ellis M.K., Robinson M., Provan W.M., and Smith L.L. The effect of a low-protein diet and dietary supplementation of threonine on tyrosine and 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione-induced corneal lesions, the extent of tyrosinaemia, and the activity of enzymes involved in tyrosine catabolism in the rat. Toxicol. Appl. Pharmacol. 150 (1998) 125-132
24. Lock E.A., Ellis M.K., Gaskin P., Robinson M., Auton TR., Provan W.M., Smith L.L., Prisbylla MP., Mutter LC., and Lee DL. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC), its toxicology and development as a drug. J. Inherited Metab. Dis. 21 (1998) 498-506
25. Lock E.A., Gaskin P., Ellis M.K., Provan W.M., Robinson M., and Smith L.L. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione ( NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse. Toxicology 144 (2000) 179-187
26. Lohr K.M., Hyndiuk R.A., Hatchel D.L., and Kurth C.E. Corneal organ cultures in tyrosinemia release chemotactic factors. J. Lab. Clin. Med. 105 (1985) 573-580
27. Neidig M.L., Decker A., Kavana M., Moran G.R., and Solomon E.I. Spectroscopic and computational studies of NTBC bound to the non-heme iron enzyme (4-hydroxyphenyl)pyruvate dioxygenase: active site contributions to drug inhibition. Biochem. Biophys. Res. Commun. 338 (2005) 206-214
28. Reddy D.V.N., Rosenburg C., and Kinsey V.E. Steady state distribution of free amino acids in the aqueous humours, vitreous body and plasma of the rabbit. Exp. Eye Res. 1 (1961) 175-181
29. Rich L.F., Beard M.E., and Burns R.P. Excess dietary tyrosine and corneal lesions. Exp. Eye Res. 17 (1973) 87-97
30. Robinson M. The corneal effects of 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione (NTBC) in the rat. In: Weisse I., Hockwin O., Green K., and Tripathi R.C. (Eds). Ocular Toxicology (1995), Plenum Press, New York 327-334
31. Schepartz B. New method for assay of tyrosine transaminase. Anal. Biochem. 30 (1969) 443-448
32. Schulz A., Ort O., Beyer P., and Kleinig H. SC-0051, A 2-benzoyl-cyclohexane-1,3-dione bleaching herbicide, is a potent inhibitor of the enzyme p-hydroxy phenylpyruvate dioxygenase. FEBS Lett. 318 (1993) 162-166
33. Whelan D.T., and Zannoni V.G. Microassay of tyrosine aminotransferase and p-hydroxyphenylpyruvic acid oxidase in mammalian liver and patients with hereditary tyrosinaemia. Biochem. Med. 9 (1974) 19-31